Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells.

Carcinoid tumors are predominantly found in the gastrointestinal tract and are characterized by hypersecretion of various substances, including bioamines and neuropeptides, leading to functional tumor disease. Here, we demonstrate that human BON carcinoid tumor cells express functionally active insulin-like growth factor-I (IGF-I) receptors and secrete IGF-I, suggesting an autocrine action of this growth factor. The IGF-I receptor was functionally active. IGF-I stimulated phosphatidylinositol 3-kinase (PI3-kinase), p70 S6 kinase (p70s6k), and extracellular signal-regulated kinase 2 activity in BON cells. Furthermore, immunoneutralization of endogenously released IGF-I markedly reduced the high basal activity of p70s6k and extracellular signal-regulated kinase 2 in serum-starved BON cells. Exogenously added IGF-I induced a marked increase in chromogranin A secretion, a marker protein for neuroendocrine secretion, by a process that was largely dependent on PI3-kinase activity. In addition, immunoneutralization of endogenously released IGF-I markedly reduced basal chromogranin A release by BON cells. Thus, the autocrine IGF-I loop regulates basal neuroendocrine secretion in BON cells. Next, we investigated the role of IGF-I as a growth promoting agent for BON cells. Our data demonstrate that IGF-I stimulates anchorage-dependent and anchorage-independent growth of BON cells by a pathway that involves PI3-kinase, mammalian target of rapamycin/p70s6k, and mitogen-activated protein kinase kinase 1 activity. Interestingly, mitogen-activated protein kinase kinase 1 activity was less important for anchorage-independent growth of BON cells. Endogenously released IGF-I was found to be largely responsible for autonomous growth of BON cells in serum-free medium and for the constitutive expression of cyclin D1 in these cells. In conclusion, IGF-I is a major autocrine regulator of neuroendocrine secretion and growth of human BON neuroendocrine tumor cells. Because our data also demonstrate that a significant proportion of neuroendocrine tumors express the IGF-I receptor and its ligand, interference with this pathway could be useful in the treatment of hypersecretion syndromes and growth of human neuroendocrine tumors.

[1]  G. Greeley,et al.  Multiple Protein Kinase Pathways Are Involved in Gastrin-releasing Peptide Receptor-regulated Secretion* , 1999, The Journal of Biological Chemistry.

[2]  T. Seufferlein,et al.  Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cancer cells. , 1999, Cancer research.

[3]  T. Seufferlein,et al.  Transforming growth factor alpha activates Ha-Ras in human pancreatic cancer cells with Ki-ras mutations. , 1999, Gastroenterology.

[4]  K. Yanagihara,et al.  Dedifferentiation of adenocarcinomas by activation of phosphatidylinositol 3-kinase. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[5]  P. Jehle,et al.  Proinsulin stimulates growth of small intestinal crypt-like cells acting via specific receptors. , 1999, The American journal of physiology.

[6]  R. Rintoul,et al.  The presence of a constitutively active phosphoinositide 3-kinase in small cell lung cancer cells mediates anchorage-independent proliferation via a protein kinase B and p70s6k-dependent pathway. , 1998, Cancer research.

[7]  J. Ross,et al.  The HER‐2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy , 1998, The oncologist.

[8]  L. Flechner,et al.  Protein Kinase C-δ Is an Important Signaling Molecule in Insulin-Like Growth Factor I Receptor-Mediated Cell Transformation , 1998, Molecular and Cellular Biology.

[9]  M. Binoux,et al.  IGFBP‐2 expression in a human cell line is associated with increased IGFBP‐3 proteolysis, decreased IGFBP‐1 expression and increased tumorigenicity , 1998, International journal of cancer.

[10]  B. Wiedenmann,et al.  Molecular and cell biological aspects of neuroendocrine tumors of the gastroenteropancreatic system , 1998, Journal of Molecular Medicine.

[11]  D. Aunis,et al.  Possible Involvement of Phosphatidylinositol 3‐Kinase in Regulated Exocytosis: Studies in Chromaffin Cells with Inhibitor LY294002 , 1998, Journal of neurochemistry.

[12]  J. Idle,et al.  Gastrin is the most important factor in ECL tumorigenesis. , 1998, Gastroenterology.

[13]  C. Gicquel,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1998 by The Endocrine Society Increased Levels of Insulin-Like Growth Factor II (IGF-II) and IGF-Binding Protein-2 Are Associated with Malignancy in Sporadic Adrenocortical Tum , 2022 .

[14]  D. Yee,et al.  Insulin Receptor Substrate-1 is the Predominant Signaling Molecule Activated by Insulin-like Growth Factor-I, Insulin, and Interleukin-4 in Estrogen Receptor-positive Human Breast Cancer Cells* , 1998, The Journal of Biological Chemistry.

[15]  D. Leroith,et al.  The Insulin-like Growth Factor-I Receptor Is Required for EWS/FLI-1 Transformation of Fibroblasts* , 1997, The Journal of Biological Chemistry.

[16]  B. van der Burg,et al.  Mitogenic Signaling of Insulin-like Growth Factor I in MCF-7 Human Breast Cancer Cells Requires Phosphatidylinositol 3-Kinase and Is Independent of Mitogen-activated Protein Kinase* , 1997, The Journal of Biological Chemistry.

[17]  G. Thomas,et al.  TOR signalling and control of cell growth. , 1997, Current opinion in cell biology.

[18]  S. Grinstein,et al.  Inhibition of neutrophil oxidative burst and granule secretion by Wortmannin: Potential role of MAP kinase and renaturable kinases , 1997, Journal of cellular physiology.

[19]  M. Rubini,et al.  The IGF-I receptor in cell growth, transformation and apoptosis. , 1997, Biochimica et biophysica acta.

[20]  D. Leroith,et al.  Mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways are not sufficient for insulin-like growth factor I-induced mitogenesis and tumorigenesis. , 1997, Endocrinology.

[21]  S. Gansauge,et al.  Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis. , 1997, Cancer research.

[22]  D. Bol,et al.  Overexpression of insulin-like growth factor-1 induces hyperplasia, dermal abnormalities, and spontaneous tumor formation in transgenic mice , 1997, Oncogene.

[23]  C. Sherr.  Cancer Cell Cycles , 1996, Science.

[24]  A. Hoeflich,et al.  Expression of IGFBP-2, -3, and -4 mRNA during differentiation of Caco-2 colon epithelial cells. , 1996, The American journal of physiology.

[25]  T. Seufferlein,et al.  Rapamycin inhibits constitutive p70s6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells. , 1996, Cancer research.

[26]  J. Battey,et al.  Insulin-like Growth Factor Expression in Human Cancer Cell Lines (*) , 1996, The Journal of Biological Chemistry.

[27]  J. Alongi,et al.  The phosphatidylinositol 3-kinase inhibitor wortmannin blocks mast cell exocytosis but not IL-6 production. , 1996, Journal of immunology.

[28]  Philip R. Cohen,et al.  PD 098059 Is a Specific Inhibitor of the Activation of Mitogen-activated Protein Kinase Kinase in Vitro and in Vivo(*) , 1995, The Journal of Biological Chemistry.

[29]  S. Schreiber,et al.  Control of p70 S6 kinase by kinase activity of FRAP in vivo , 1995, Nature.

[30]  W. Wetsel,et al.  Effects of insulin-like growth factors I and II and insulin on the immortalized hypothalamic GTI-7 cell line. , 1995, Neuroendocrinology.

[31]  B. Evers,et al.  Phorbol ester-induced alteration in the pattern of secretion and storage of chromogranin A and neurotensin in a human pancreatic carcinoid cell line. , 1995, Endocrinology.

[32]  R. Baserga,et al.  The insulin-like growth factor I receptor: a key to tumor growth? , 1995, Cancer research.

[33]  A. Ferber,et al.  Mitogenicity and transforming activity of the insulin-like growth factor-I receptor with mutations in the tyrosine kinase domain. , 1994, The Journal of biological chemistry.

[34]  T. Hunter,et al.  Cyclins and cancer II: Cyclin D and CDK inhibitors come of age , 1994, Cell.

[35]  K. Langley.  The Neuroendocrine Concept Today , 1994, Annals of the New York Academy of Sciences.

[36]  B. Evers,et al.  The Human Carcinoid Cell Line, BON , 1994 .

[37]  C. Kahn,et al.  The insulin signaling system. , 1994, The Journal of biological chemistry.

[38]  E. Theodorsson,et al.  Presence of IGF‐I In human midgut carcinoid tumours—an autocrine regulator of carcinoid tumour growth? , 1992, International journal of cancer.

[39]  R. Brown,et al.  Protein measurement using bicinchoninic acid: elimination of interfering substances. , 1989, Analytical biochemistry.

[40]  A. Dahlström,et al.  Presence of nerve growth factor‐like immunoreactivity in carcinoid tumour cells and induction of a neuronal phenotype in long‐term culture , 1989, International journal of cancer.

[41]  M. Kasuga,et al.  Rapid stimulation of fluid-phase endocytosis and exocytosis by insulin, insulin-like growth factor-I, and epidermal growth factor in KB cells. , 1988, Experimental cell research.

[42]  M. Binoux,et al.  Heterogeneity of insulin-like growth factor binding proteins between structure and affinity. 2. Forms released by human and rat liver in culture. , 1987, European journal of biochemistry.

[43]  J. Minna,et al.  Positive correlation between histological tumor involvement and generation of tumor cell colonies in agarose in specimens taken directly from patients with small-cell carcinoma of the lung. , 1980, Cancer research.

[44]  G. Scatchard,et al.  THE ATTRACTIONS OF PROTEINS FOR SMALL MOLECULES AND IONS , 1949 .

[45]  H. Werner,et al.  The insulin-like growth factor-I receptor signaling pathways are important for tumorigenesis and inhibition of apoptosis. , 1997, Critical reviews in oncogenesis.

[46]  I. Weinstein.  Relevance of cyclin D1 and other molecular markers to cancer chemoprevention , 1996, Journal of cellular biochemistry. Supplement.

[47]  S. Schreiber,et al.  Erratum: Control of p70 S6 kinase by kinase activity of FRAP in vivo (Nature (1995) 377 (441-446)) , 1995 .

[48]  B. Evers,et al.  The human carcinoid cell line, BON. A model system for the study of carcinoid tumors. , 1994, Annals of the New York Academy of Sciences.

[49]  S. Ferrari,et al.  S6 phosphorylation and the p70s6k/p85s6k. , 1994, Critical reviews in biochemistry and molecular biology.

[50]  K. Öberg,et al.  Expression of growth factor peptides and their receptors in neuroendocrine tumors of the digestive system. , 1993, Acta oncologica.

[51]  W. Sly,et al.  Insulin-like growth factor receptor expression and function in human breast cancer. , 1990, Cancer research.